A Newcastle research team has been exploring the role of vitamin A in the pathogenesis of psychiatric disorders.
Category: Precision Medicine
Researchers discover neuronal biomarkers of schizophrenia in the blood
HMRI and University of Newcastle researcher, Professor Murray Cairns, along with his Precision Medicine team have discovered a unique biomarker in the blood of people with schizophrenia. The findings, published in Science Advances this week, offer a rare insight into the molecular characteristics of the brain by using neuronally derived material present in circulating blood.
Drug combination discovery extending life expectancy of children with brain cancer
Newcastle and Hunter-based researchers have discovered a drug combination that could dramatically improve the life expectancy of children with brain cancer.
Discovery key to reducing leukaemia treatment resistance
In a world first, Newcastle researchers have discovered the mechanisms acute myeloid leukaemia (AML) cells use to produce ‘free radicals’ – the byproduct of a cell process that aggressively fuels the growth of cancer cells and limits the effectiveness of current treatments.
New funding for precision medicine platform to improve targeted treatments for schizophrenia
HMRI’s Professor Murray Cairns was awarded $1 million funding from the NSW Government to explore genetically informed precision medicine for schizophrenia using human cerebral organoids.
Professor Murray Cairns’ research team discovers potential treatments for obesity and diabetes
Professor Murray Cairns’ recent drug repurposing trials have found that common medications used for heart conditions, muscle tension, stomach ulcers and cancer treatment can be used to fight obesity and diabetes.
Pneumonia risk signals potential for precision medicine
The largest ever genomic study of pneumonia has identified the genetic risk signals of the disease, paving the way for potential new treatments and the use of precision medicine.
Australian research leads to trial treatment for DIPG
For the first time, families of children suffering the worst type of children’s cancer will now have drug combination options with the announcement of a new clinical trial based on Australian research.https://hmri.org.au/researchers/matt-dun
Newcastle cancer researcher recognised as Young Tall Poppy
Esteemed cancer researcher and charity advocate, Dr Matthew Dun, has been acknowledged for his dedication to improving cancer survival outcomes, with a 2020 ‘Young Tall Poppy’ science award. Dr Dun, a researcher from The University of Newcastle and The Hunter Medical Research Institute (HMRI), was selected by the Australian Institute of Policy and Science (AIPS) […]
